Doel van het onderzoek: This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations.
Sponsor: National Cancer Institute (NCI)
Contactgegevens voor de proefperiode: Study Coordinator: Ms. Abha Adat, aadat@mdanderson.org, or the Principal Investigator Filip Janku, 713-563-1930, FJanku@mdanderson.org.
Gewenste betrokkenheid van de patiënt: ECD patients with BRAF V600 mutation who have not previously been treated with a BRAF- or MEK-inhibitor and are 18-years or older.
Bekende centra die ECD-patiënten in het onderzoek opnemen: MD Anderson, Houston, Texas
ClinicalTrials.gov-identificatiecode: NCT03794297

